ProCE Banner Activity

Current and Emerging Role of PARP Inhibitors Alone or With Secondary Hormonal Therapies for Patients With mCRPC

Slideset

Download these slides from a live symposium to learn more about the use of PARP inhibitors for patients with prostate cancer.

Released: June 02, 2023

Share

Faculty

Alan H. Bryce

Alan H. Bryce, MD

Chief Clinical Officer
Professor, Department of Medical Oncology and Therapeutics Research 
Professor of Molecular Medicine, TGEN
City of Hope
Phoenix, Arizona

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Merck Sharp & Dohme Corp., and Novartis Pharmaceuticals Corporation.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation